Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of early switch from cobimetinib + vemurafenib to atezolizumab in BRAF V600-mutant unresectable or metastatic melanoma
2015-005097-37Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cobimetinib, vemurafenib and atezolizumab in melanoma (2 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: PFS1. Started Mar 2016; status: completed.
02
Drugs
cobimetinibvemurafenibatezolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-005097-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005097-37.